Escrig Ana Camarasa, Vergara Demetrio González, Rebollo José Carlos Serrano, Barbé Ferran
Hospital Universitario San Juan de Alicante, Alicante, España.
Arch Bronconeumol. 2009;45 Suppl 3:14-21. doi: 10.1016/S0300-2896(09)72853-4.
Sleep apnea-hypopnea syndrome (SAHS) is a highly prevalent disease in the general population and, due to its social and health repercussions, has become a major public health problem. The definition of this syndrome, as well as that of respiratory event, have been refined. The role of inflammatory mechanisms in the development of cardiovascular disease is currently under investigation and biological markers will probably be added, both in the definition of SAHS and in the choice of treatment. Although the gold standard in diagnosis is polysomnography, respiratory polygraphy has become a valid and complementary alternative, since this technique is a simplified method that can be performed in the home to confirm or exclude this disease. Expert systems such as single-channel devices may help to simplify diagnosis. Currently, the mainstay of treatment is still continuous positive airway pressure (CPAP); this modality is mainly indicated in patients with moderate or severe SAHS and has been shown to reduce mortality in this group.
睡眠呼吸暂停低通气综合征（SAHS）在普通人群中是一种高度流行的疾病，由于其对社会和健康的影响，已成为一个主要的公共卫生问题。该综合征以及呼吸事件的定义已经得到完善。炎症机制在心血管疾病发展中的作用目前正在研究中，并且可能会在SAHS的定义和治疗选择中加入生物标志物。虽然诊断的金标准是多导睡眠图，但呼吸多导仪已成为一种有效的补充替代方法，因为该技术是一种可以在家中进行的简化方法，用于确认或排除这种疾病。诸如单通道设备之类的专家系统可能有助于简化诊断。目前，治疗的主要方法仍然是持续气道正压通气（CPAP）；这种方式主要适用于中度或重度SAHS患者，并已证明可降低该组患者的死亡率。
